Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Ti...

Date : 07/30/2019 @ 12:30PM
Source : GlobeNewswire Inc.
Stock : Atossa Genetics Inc (ATOS)
Quote : 1.26  0.01 (0.80%) @ 5:00AM
After Hours
Last Trade
Last $ 1.30 ▲ 0.05 (4.00%)

Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Ti...

Atossa Genetics (NASDAQ:ATOS)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Atossa Genetics Charts.

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced the online launch of company CEO Steven Quay’s Tedx UofW Talk, “How to Be Smart When You’re Dense: Preventing Breast Cancer by 2030.” 

In the Tedx UofW talk, Steven Quay, M.D., Ph.D., Atossa’s Chief Executive Officer outlines the journey of Atossa Genetics in identifying improved ways to identify women at high risk of breast cancer, using mammography to identify dense breast tissue.  Dr. Quay also details his experience with triumph, failure and perseverance while trying to prevent one of the world’s most common diseases: breast cancer. He emphasizes the need for unshaken efforts to solve such complex problems, and ways that he and his team are doing so in breast cancer research.

The talk has been posted online at https://www.youtube.com/watch?v=hK4PlbYE_5M&list=PLsRNoUx8w3rNCo4uCVXiNDFZLiKrIOQ1J&index=5 and can also be accessed via the company’s website at www.atossagenetics.com.

“I am grateful for having had the opportunity to address our approach to breast cancer as something that, like cervical cancer, has the potential to be completely eradicated over time.  It was an honor to participate in this University of Washington program and I hope the information provided helps those who participated in the event, as well as those who view it online,” commented Dr. Quay.

Steven Quay is the founder of Seattle-based Atossa Genetics, Inc., dedicated to breast cancer prevention. He received a Ph.D. in Biological Chemistry and a M.D. from the University of Michigan, a postdoc at MIT and Harvard, and he was a faculty member at Stanford Medical School.  His contributions to medicine, cancer, and biochemistry have been cited more than 9,300 times, putting him in the top 1% of the world’s scientists.  Since entering the biotech industry in 1983, he has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 U.S. patents.  Over 80 million people have benefited from the medicines he invented.  His current passion involves the prevention of the two million yearly breast cancer cases worldwide.  This talk was given at a TEDx event using the TED conference format but independently organized by a local community.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa's drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics, Inc.Kyle GuseCFO and General Counsel(O) 866-893-4927kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott GordonCoreIR377 Oak StreetConcourse 2Garden City, NY 11530Office: 516.222.2560scottg@CoreIR.com

Latest ATOS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.